Greater cumulative benefits from ixekizumab versus ustekinumab treatment over 52 weeks for patients with moderate-to-severe psoriasis in a randomized, double-blinded phase 3b clinical trial

The Journal of Dermatological Treatment
Andrew BlauveltAndreas Pinter

Abstract

Background: Ixekizumab (IXE), a high-affinity monoclonal antibody that selectively targets interleukin-17A, has shown superiority to ustekinumab (UST) and etanercept in skin clearance from randomized clinical trials in patients with moderate-to-severe psoriasis.Objective: To compare cumulative benefits of IXE versus UST over 52 weeks of treatment.Methods: Cumulative clinical benefit of IXE and UST was assessed by evaluating the area under the curve (AUC) for responders of Psoriasis Area and Severity Index (PASI), itch numeric rating scale (Itch NRS), and Dermatology Life Quality Index (DLQI) outcomes over 52 weeks using data from IXORA-S trial comparing IXE (N = 136) and UST (N = 166). Normalized cumulative benefit was calculated to obtain the percentage of the maximum AUC for each outcome measure. Missing values were imputed using non-responder imputation.Results: Significantly greater cumulative benefits were obtained for IXE compared with UST. Normalized cumulative benefit with IXE versus UST for PASI 75/90/100, Itch NRS (0), and DLQI (0,1) were 83.1% and 67.6%; 68.9% and 46.5%; 41.1% and 23.4%; 40.4% and 30.9%; and 62.2% and 46.6%, respectively. Cumulative clinical benefit ratios for IXE:UST were 1.23 for PASI 75, 1.48 for ...Continue Reading

References

May 1, 1994·Clinical and Experimental Dermatology·A Y Finlay, G K Khan
Aug 19, 2006·BMJ : British Medical Journal·Catherine H Smith, J N W N Barker
May 15, 2013·Actas dermo-sifiliográficas·S RosJ M Carrascosa
Jun 26, 2013·Current Problems in Dermatology·Peter L MatteiAlexa B Kimball
Jan 25, 2017·The Western Journal of Emergency Medicine·Andrew R KettererMichael A Gisondi
May 26, 2017·The British Journal of Dermatology·K ReichUNKNOWN IXORA-S investigators
Nov 6, 2018·Journal of the European Academy of Dermatology and Venereology : JEADV·J-T MaulM Augustin

❮ Previous
Next ❯

Citations

Jul 13, 2019·International Journal of Molecular Sciences·Kübra Bunte, Thomas Beikler
Dec 31, 2020·Journal of Managed Care & Specialty Pharmacy·Andrew BlauveltBaojin Zhu
Apr 20, 2021·The Cochrane Database of Systematic Reviews·Emilie SbidianLaurence Le Cleach

❮ Previous
Next ❯

Related Concepts

Related Feeds

Alternative Complement Pathway

The Alternative Complement Pathway is part of the innate immune system, and activation generates membrane attack complexes that kill pathogenic cells. Discover the latest research on the Alternative Complement Pathway.